Delcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INC

Financial Performance:

• Total Q3 2026 revenue reached $35.1 million, a 71% year-over-year increase from $20.6 million in Q3 2025.
• HepzatoKit revenue was $32.7 million (72% YoY growth), while Chemostat revenue was $2.4 million (85% YoY growth).
• Gross margin expanded to 89% compared to 87% in the prior year quarter.
• Net income rose to $7.0 million from $0.8 million in Q3 2025; Adjusted EBITDA increased to $11.5 million from $5.3 million.
• Cash flow from operations was positive at $8.2 million for the quarter, up from $4.8 million.
• The company ended the quarter with $104.3 billion in cash investments and maintained a debt-free balance sheet.

Guidance and Future Outlook:

• Full-year 2026 total revenue guidance raised to $115 million–$117 million.
• Q4 2026 revenue guidance set at $25.8 million–$27.8 million, reflecting approximately 25–34% YoY growth.
• Full-year gross margin guidance updated to 87%–89%, with continued positive Adjusted EBITDA expected.
• Management anticipates at least 41% HepzatoKit volume growth in 2026 versus 2025.
• Future outlook assumes consistent new patient starts in Q4 after adjusting for holiday scheduling disruptions.

Business Segments and Product Lines:

• HepzatoKit: Driving the majority of growth; 1,000th commercial hepatic treatment administered in the U.S. in Q3.
• Treatment Network: 33 active treatment centers currently; expanded to include University of Nebraska and AdventHealth (a system with 50+ hospitals and 4M+ patients).
• Expansion Goals: Expectation to reach at least 36 active centers by year-end, pending final activations.
• Clinical Pipeline: Phase 2 colorectal trial on track for interim analysis in mid-2027; breast cancer trial enrollment slower than anticipated with new sites in Europe and U.S.
• New Programs: Planned IND submission for cholangiocarcinoma in early 2027; preclinical development of an oxaliplatin-based PHB program targeting mid-2027 IND filing.
• Standard of Care: Combination therapy with systemic treatments is increasingly becoming the norm, extending patient treatment duration.

Market and Competitive Landscape:

• Market adoption driven by positive real-world data and word-of-mouth among informed patient communities.
• Physicians view HepzatoKit as complementary to systemic therapies (e.g., Opdivo, Keytruda) rather than mutually exclusive.
• Large integrated health systems like AdventHealth provide significant referral volume due to internal network coordination.
• Competition remains managed through growing center capacity and training backup teams for perfusionists, anesthesiologists, and IRs.

Risks and Challenges:

• Enrollment Delays: Breast cancer trial enrollment is slower than initially projected, preventing specific interim analysis timing guidance.
• Operational Variability: Center activation numbers carry uncertainty; recent projections have seen cancellations, though new starts often outperform.
• Seasonality: Q4 historically sees lower new patient starts and reduced treatment capacity due to holiday scheduling.
• Regulatory Uncertainty: Ongoing monitoring of potential impacts from 340B rule changes, though currently viewed as net neutral to positive.

Management Commentary and Tone:

• Management tone was highly confident, citing record revenue, positive operating cash flow, and successful commercial expansion.
• Leadership emphasized the "operating leverage" of their commercial model and the strategic value of expanded network capacity.
• Gerard Michel (CEO) highlighted the shift from "clinical trial headwinds" to "commercial momentum" and the normalization of combination therapies.
• Sandra Pinnell (CFO) characterized R&D spending as increasing toward a new baseline for 2027, while SG&A is expected to remain relatively flat with slight flexibility.

Analyst Questions and Answers:

• Revenue Drivers: Outperformance attributed to four factors: adoption of combination/sequencing therapy, patient demand from word-of-mouth, resolution of clinical trial headwinds, and optimized scheduling via backup staff.
• Guidance Logic: The Q4 revenue step-down is primarily attributed to losing two weeks of treatment capacity due to holidays and historical seasonality in new patient starts.
• Pipeline Timing: Colorectal cancer interim results expected in Q2/Q3 2027 (previously projected for year-end 2027).
• 340B Regulations: Company believes final rules will be net neutral to positive regarding ASPs without volume impact.
• Growth Sources: 0.6 new patient starts per site are broad-based, with mature centers (e.g., MD Anderson, Mass General) increasing capacity and treatment volume.

Other Key Points:

• The 500th chemo staff procedure was delivered at University Hospital Southampton by Dr. Sasha Nmodi, reinforcing international adoption.
• The oxaliplatin-based PHB program is strategically aligned with physician familiarity with oxaliplatin as a backbone agent for GI cancers.
• Management noted that while center activation projections can vary, the company has a strong track record of overperforming on patient starts per center.